is retatrutide available in other countries UK 2026: Phase 3 Results October 27, 2025: U.K. regulators

Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded studies raise questions.

The use of GLP-1 analogs is growing rapidly in obese and overweight patients who need to control body weight.

Rozwj farmakologicznych sposobw normalizacji masy ciaa jest jednym z najbardziej naglcych problemw XXI wieku, szczeglnie w spoeczestwach wysoko rozwinitych

Nevertheless, bone consequences of intentional weight loss interventions in PwO are well known: (i) significant weight loss induced by caloric restriction and bariatric surgery results in accelerated bone turnover and bone loss, and (ii) unlike caloric restriction interventions, PwO experience a substantial deterioration in bone microarchitecture and strength associated with an increased risk of fracture after bariatric surgery especially malabsorptive procedures

What to do when a blockbuster drug for one condition disrupts the hormone behind another blockbuster drug: a case of informed consent.

Address obesity and all comorbidities.